Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses

Journal of General Internal Medicine

Volumn 31, Issue 5, 2016, Pages 561-572

  Braithwaite, Dejana ^a   Walter, Louise C ^b   Izano, Monika ^a,c   Kerlikowske, Karla ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aging; breast cancer screening; comorbidity

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL DECISION SUPPORT SYSTEM; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; DATA SYNTHESIS; DIABETES MELLITUS; DISEASE SEVERITY; EMBASE; FALSE POSITIVE RESULT; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MAMMOGRAPHY; MEDLINE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUALITY CONTROL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; ADVERSE EFFECTS; AGE; BREAST TUMOR; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; FEMALE; MASS SCREENING; PROCEDURES;

AGE FACTORS; BREAST NEOPLASMS; COMORBIDITY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84964306923     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3580-3     Document Type: Article

References (53)

1. American Cancer Society: Cancer Facts and Figures, 2014.
2. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285:2750–6.
3. Mandelblatt JS, Schechter CB, Yabroff KR, et al. Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med. 2005;20:487–96.
4. Braithwaite D, Mandelblatt JS, Kerlikowske K. To screen or not to screen older women for breast cancer: a conundrum. Future Oncol. 2013;9:763–6.
5. Mandelblatt JS, Silliman R. Hanging in the balance: making decisions about the benefits and harms of breast cancer screening among the oldest old without a safety net of scientific evidence. J Clin Oncol. 2009;27:487–90.
6. Berry DA, Baines CJ, Baum M, et al. Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol. 2009;27:639–40. author reply 641-632.
7. Zappa M, Visioli CB, Ciatto S. Mammography screening in elderly women: Efficacy and cost-effectiveness. Crit Rev Oncol Hematol. 2003;46:235–9.
8. Walter LC, Schonberg MA. Screening mammography in older women: a review. JAMA. 2014;311:1336–47.
9. Cobain EF, Hayes DF. Indications for prognostic gene expression profiling in early breast cancer. Curr Treat Options Oncol. 2015;16:340.
10. Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14:13–22.
11. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35:181–200.
12. Satariano WA, Silliman RA. Comorbidity: Implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol. 2003;48:239–48.
13. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831–8.
14. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155:481–92.
15. Braithwaite D, Zhu W, Hubbard RA, et al. Screening Outcomes in Older US Women Undergoing Multiple Mammograms in Community Practice: Does Interval, Age or Comorbidity Score Affect Tumor Characteristics or False Positive Rates? J Natl Cancer Inst. 2013;105(5):334–41.
16. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738–47.
17. Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med. 2005;118:1078–86.
18. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727–37. W237-742.
19. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical˙epidemiology/oxford.asp (accessed 11 Nov 2015).
20. Richardson W, Detsky A. Users' Guides to the Medical Literature: VII. How to use a clinical decision analysis. JAMA. 1992;273:1292–5.
21. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515–24.
22. Barratt A, Irwig L, Glasziou P, et al. Relative benefit of mammography reduces with age. Evid Based Healthc. 2002;6:156–7.
23. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant. 2002;17:1786–9.
24. LeBrun CJ, Diehl LF, Abbott KC, Welch PG, Yuan CM. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000;35:237–43.
25. Walter LC, Eng C, Covinsky KE. Screening mammography for frail older women: What are the burdens? J Gen Intern Med. 2001;16:779–84.
26. Yasmeen S, Xing G, Morris C, Chlebowski RT, Romano PS. Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. Cancer. 2011;117:3252–61.
27. Terret C, Castel-Kremer E, Albrand G, Droz JP. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol. 2009;10:80–7.
28. Smith-Bindman R, Quale C, Chu PW, Rosenberg R, Kerlikowske K. Can Medicare billing claims data be used to assess mammography utilization among women ages 65 and older? Med Care. 2006;44:463–70.
29. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155:10–20.
30. Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA. 1999;282:2156–63.
31. Walter LC, Lindquist K, O'Hare AM, Johansen KL. Targeting screening mammography according to life expectancy among women undergoing dialysis. Arch Intern Med. 2006;166:1203–8.
32. Chertow GM, Paltiel AD, Owen WF Jr, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med. 1996;156:1345–50.
33. Sennerstam RB, Wiksell H, Schassburger KU, Auer GU. Breast cancer and clinical outcome among women over 60 years of age a plead for more screening and alternative treatments. Anal Quant Cytol Histol. 2012;34:189–94.
34. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98:774–82.
35. Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005;43:132–40.
36. Yasmeen S, Hubbard RA, Romano PS, et al. Risk of Advanced-Stage Breast Cancer among Older Women with Comorbidities. Cancer Epidemiol Biomarkers Prev. 2012.
37. McPherson CP, Swenson KK, Lee MW. The effects of mammographic detection and comorbidity on the survival of older women with breast cancer. J Am Geriatr Soc. 2002;50:1061–8.
38. Messecar DC. Mammography screening for older women with and without cognitive impairment. J Gerontol Nurs. 2000;26:14–24. quiz 52-13.
39. Mandelblatt JS, Wheat ME, Monane M, Moshief RD, Hollenberg JP, Tang J. Breast cancer screening for elderly women with and without comorbid conditions. A decision analysis model. Ann Intern Med. 1992;116:722–30.
40. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161:104–12.
41. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
42. Kerlikowske K, Hubbard RA, Miglioretti DL, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155:493–502.
43. Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med. 2002;137:783–90.
44. Walter LC. What is the right cancer screening rate for older adults. Arch Intern Med. 2011;171:2037–9.
45. Schonberg MA, McCarthy EP, York M, Davis RB, Marcantonio ER. Factors influencing elderly women's mammography screening decisions: implications for counseling. BMC Geriatr. 2007;7:26.
46. Schonberg MA, Walter LC. Talking about stopping cancer screening-not so easy. JAMA Intern Med. 2013;173:532–3.
47. Scinto JD, Gill TM, Grady JN, Holmboe ES. Screening mammography: Is it suitably targeted to older women who are most likely to benefit? J Am Geriatr Soc. 2001;49:1101–4.
48. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O'Brien S, Walter LC. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ. 2012;346, e8441.
49. Schonberg MA, Hamel MB, Davis RB, et al. Development and Evaluation of a Decision Aid on Mammography Screening for Women 75 Years and Older. JAMA Intern Med. 2013.
50. Cruz M, Covinsky K, Widera EW, Stijacic-Cenzer I, Lee SJ. Predicting 10-year mortality for older adults. JAMA. 2013;309:874–6.
51. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults: a systematic review. JAMA. 2012;307:182–92.
52. Kramer BS, Elmore JG. Projecting the benefits and harms of mammography using statistical models: proof or proofiness? J Natl Cancer Inst. 2015;107.
53. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr. 1975;2006:47–55.